Divi’s Labs Begins Commercial Operations at Unit-III Greenfield Project

Divi’s Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesises generic APIs and intermediates. In a significant move, Divi’s Laboratories has announced the commencement of commercial operations at its new manufacturing facility in Kakinada, Andhra Pradesh. This milestone marks the completion of Phase One of Unit III, a greenfield project aimed at expanding the company’s production capabilities.

Phase One of Unit III: Expanding Horizons

The Kakinada plant, located in Ontimamidi Village, is part of the first phase of the Export-Oriented Unit (EOU). This spans about 200 acres of the 500-acre Unit III site, this phase represents an estimated investment of ₹1,200-₹1,500 crore. With this development, Divi’s Labs continues to strengthen its position as a global leader in the pharmaceutical industry.

The new facility complements Divi’s  Labs existing 2 manufacturing sites near Hyderabad and Visakhapatnam. These facilities boast over 64 production buildings, 70 pharma suites, and a reaction capacity exceeding 14,500 m³, making them among the largest active pharmaceutical ingredient (API) manufacturing facilities in the world.

Enhancing Production Capabilities

Divi’s Laboratories is renowned for its expertise in manufacturing non-potent and highly potent APIs, as well as low-dose pharmaceutical products. The Kakinada facility has been in the pipeline since 2021 and signifies the company’s commitment to scaling operations and meeting global demands. This new addition highlights Divi’s dedication to innovation, quality, and expansion.

Divi’s Lab Share Performance

As of January 03, 2025, 11:21 AM, the shares of Divis Lab are trading at ₹6,072.00 per share with a decline of 1.18% from its previous day’s closing price. Over the last month, the stock has seen a decline of 2.20%. While over the year the stock has surged over 50% the stock has a 52-week high and 52-week low of ₹6,285.45 per share and ₹3,350.00 per share respectively. The current market capitalisation of Divi’s Lab stands over 1,60,000 crores.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.